Literature DB >> 31982726

The positive feedback loop of RHPN1-AS1/miR-1299/ETS1 accelerates the deterioration of gastric cancer.

Lei Ding1, Ling Wang2, Zhiqi Li3, Xuefeng Jiang4, Yangchun Xu5, Ning Han6.   

Abstract

Gastric cancer (GC) is the most prevailing malignant tumor of digestive tract and accounts for a considerable part of cancer-relevant deaths worldwide. An increasing number of literatures highlight the important role of lncRNAs in the occurrence and development of GC. Considering that the function of RHPN1-AS1 in GC remains to be fully inquired, we purposed to investigate the potential and mechanism of RHPN1-AS1 in GC. The expression of RHPN1-AS1 was significantly upregulated in GC samples and cells. High RHPN1-AS1 level was strongly correlated with advanced stages of GC and predicted poor outcomes of GC. Furthermore, depletion of RHPN1-AS1 inhibited cell proliferation and cell cycle whereas promoted cell apoptosis. Subcellular fractionation analysis expounded the main expression of RHPN1-AS1 in GC cell cytoplasm. Herein, we conjectured that RHPN1-AS1 might exert its performance in GC through the ceRNA network. Our findings demonstrated that RHPN1-AS1 enhanced ETS1 expression via sponging miR-1299. More importantly, the transcriptional activation of RHPN1-AS1 was mediated by ETS1. Results of recue assays validated that RHPN1-AS1/miR-1299/ETS1 positive feedback loop aggravated the malignant behaviors of GC, revealing RHPN1-AS1 as a latent effective target for the treatment of GC patients.
Copyright © 2020. Published by Elsevier Masson SAS.

Entities:  

Keywords:  ETS1; GC; RHPN1-AS1; miR-1299

Year:  2020        PMID: 31982726     DOI: 10.1016/j.biopha.2020.109848

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  Long non-coding RNA RHPN1-AS1 promotes tumorigenesis and metastasis of ovarian cancer by acting as a ceRNA against miR-596 and upregulating LETM1.

Authors:  Junrong Wang; Weimin Ding; Yingke Xu; Enfu Tao; Miaojun Mo; Wei Xu; Xu Cai; Xiaomin Chen; Junhui Yuan; Xiuying Wu
Journal:  Aging (Albany NY)       Date:  2020-03-12       Impact factor: 5.682

2.  RHPN1‑AS1 promotes ovarian carcinogenesis by sponging miR‑485‑5p and releasing TPX2 mRNA.

Authors:  Shoubin Cui; Cui Li
Journal:  Oncol Rep       Date:  2021-04-28       Impact factor: 3.906

3.  Construction and Comprehensive Prognostic Analysis of a Novel Immune-Related lncRNA Signature and Immune Landscape in Gastric Cancer.

Authors:  Xiaolong Liang; Lang Zha; Gangfeng Yu; Xiong Guo; Chuan Qin; Anqi Cheng; Ziwei Wang
Journal:  Int J Genomics       Date:  2022-01-17       Impact factor: 2.326

4.  MiR-191-5p alleviates microglial cell injury by targeting Map3k12 (mitogen-activated protein kinase kinase kinase 12) to inhibit the MAPK (mitogen-activated protein kinase) signaling pathway in Alzheimer's disease.

Authors:  Wenjun Wan; Ganzhe Liu; Xia Li; Yu Liu; Ying Wang; Haisong Pan; Jun Hu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  RHPN1‑AS1 promotes ovarian carcinogenesis by sponging miR‑6884‑5p thus releasing TOP2A mRNA.

Authors:  Shoubin Cui; Fengling Li
Journal:  Oncol Rep       Date:  2021-08-20       Impact factor: 3.906

6.  Rhophilin rho GTPase binding protein 1-antisense RNA 1 (RHPN1-AS1) promotes ovarian carcinogenesis by sponging microRNA-485-5p and releasing DNA topoisomerase II alpha (TOP2A).

Authors:  Yi Zhou; Jing Li; Xiaoxin Yang; Yu Song; Haigang Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

7.  Hsa_circ_0005230 is up-regulated and promotes gastric cancer cell invasion and migration via regulating the miR-1299/RHOT1 axis.

Authors:  Yan-Yu Peng; Dan Sun; Yan Xin
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

8.  In the Tumor Microenvironment, ETS1 Is an Oncogenic Immune Protein: An Integrative Pancancer Analysis.

Authors:  Zixuan Wu; Yanhui Jiang; Xuyan Huang; Minjie Cai; Kai Yuan; Peidong Huang; Zuhong Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-15       Impact factor: 2.650

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.